HomeCompareMLMLF vs ABBV

MLMLF vs ABBV: Dividend Comparison 2026

MLMLF yields 2047.08% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLMLF wins by $12346572116.86M in total portfolio value
10 years
MLMLF
MLMLF
● Live price
2047.08%
Share price
$0.10
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$12346572116.96M
Annual income
$11,264,140,648,675,462.00
Full MLMLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MLMLF vs ABBV

📍 MLMLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLMLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLMLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLMLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLMLF
Annual income on $10K today (after 15% tax)
$174,002.05/yr
After 10yr DRIP, annual income (after tax)
$9,574,519,551,374,142.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MLMLF beats the other by $9,574,519,551,353,086.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLMLF + ABBV for your $10,000?

MLMLF: 50%ABBV: 50%
100% ABBV50/50100% MLMLF
Portfolio after 10yr
$6173286058.53M
Annual income
$5,632,070,324,350,117.00/yr
Blended yield
91.23%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MLMLF
No analyst data
Altman Z
-8.6
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLMLF buys
0
ABBV buys
0
No recent congressional trades found for MLMLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLMLFABBV
Forward yield2047.08%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$12346572116.96M$102.3K
Annual income after 10y$11,264,140,648,675,462.00$24,771.77
Total dividends collected$12269881710.22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MLMLF vs ABBV ($10,000, DRIP)

YearMLMLF PortfolioMLMLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$215,408$204,708.29$11,550$430.00+$203.9KMLMLF
2$4,351,596$4,121,108.69$13,472$627.96+$4.34MMLMLF
3$82,462,801$77,806,593.51$15,906$926.08+$82.45MMLMLF
4$1,466,212,867$1,377,977,670.10$19,071$1,382.55+$1466.19MMLMLF
5$24,466,837,041$22,897,989,273.50$23,302$2,095.81+$24466.81MMLMLF
6$383,283,234,487$357,103,718,853.20$29,150$3,237.93+$383283.21MMLMLF
7$5,638,317,826,915$5,228,204,766,013.68$37,536$5,121.41+$5638317.79MMLMLF
8$77,911,423,234,974$71,878,423,160,175.47$50,079$8,338.38+$77911423.18MMLMLF
9$1,011,618,194,660,301$928,252,971,798,878.10$69,753$14,065.80+$1011618194.59MMLMLF
10$12,346,572,116,961,984$11,264,140,648,675,462.00$102,337$24,771.77+$12346572116.86MMLMLF

MLMLF vs ABBV: Complete Analysis 2026

MLMLFStock

McFarlane Lake Mining Limited acquires, explores, and develops gold properties in Canada. It holds an option agreement to acquire 100% interest in the High Lake mineral property located east of the Ontario-Manitoba border; West Hawk Lake mineral property located within Southwestern Manitoba; the McMillan mineral property located within Northeastern Ontario; Mongowin property located in Northeastern Ontario; and the Michaud/Munro properties located in Matheson, Ontarios. McFarlane Lake Mining Limited is headquartered in Sudbury, Canada.

Full MLMLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MLMLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLMLF vs SCHDMLMLF vs JEPIMLMLF vs OMLMLF vs KOMLMLF vs MAINMLMLF vs JNJMLMLF vs MRKMLMLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.